Garyfallos G, Lavrentiadis G, Amoutzias D, Monas K, Manos N
B' University Department of Psychiatry, Aristotelian University of Thessaloniki, Greece.
Acta Psychiatr Scand. 1993 Dec;88(6):425-8. doi: 10.1111/j.1600-0447.1993.tb03485.x.
The dexamethasone suppression test (DST) was administered to 30 inpatients who met the DSM-III-R criteria for chronic schizophrenia and shared similar environments. Four of them (13%) were DST nonsuppressors. The mean and maximum postdexamethasone cortisol levels were correlated with the patient's score on the scale for the Schedule for the Assessment of Negative Symptoms and with the score on the anergia subscale of the Brief Psychiatric Rating Scale. None of the correlations were statistically significant. Furthermore, the scores on the above scales were not significantly correlated with clinical variables such as duration of illness, number of admissions or length of hospitalization, nor were any significant correlations found between the postdexamethasone cortisol levels and the score on the Beck Depression Inventory. In addition, depressed and nondepressed schizophrenics did not differ regarding the rate of nonsuppression and the postdexamethasone cortisol levels. This study found that: 1) dexamethasone nonsuppression in schizophrenia was not related to the presence of negative symptoms; 2) there was no relationship between negative symptoms and illness variables; and 3) the depressed schizophrenics did not display increased nonsuppression compared with nondepressed schizophrenics.
地塞米松抑制试验（DST）应用于30名符合DSM-III-R慢性精神分裂症标准且处于相似环境的住院患者。其中4人（13%）为DST非抑制者。地塞米松给药后皮质醇水平的均值和最高值与患者在阴性症状评定量表上的得分以及简明精神病评定量表中无力感分量表的得分相关。但这些相关性均无统计学意义。此外，上述量表得分与病程、住院次数或住院时长等临床变量无显著相关性，地塞米松给药后皮质醇水平与贝克抑郁量表得分之间也未发现显著相关性。另外，抑郁型和非抑郁型精神分裂症患者在非抑制率和地塞米松给药后皮质醇水平方面并无差异。本研究发现：1）精神分裂症患者中的地塞米松非抑制现象与阴性症状的存在无关；2）阴性症状与疾病变量之间无关联；3）与非抑郁型精神分裂症患者相比，抑郁型精神分裂症患者并未表现出更高的非抑制率。
